awmsg logo



tipranavir (Aptivus®)


Reference No. 52

Publication date:
07/09/2007


Appraisal information

tipranavir (Aptivus®) 250 mg capsule


Company: Boehringer Ingelheim Ltd
BNF category: Infections
NMG meeting date: 12/07/2007
AWMSG meeting date: 15/08/2007
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0707
Ministerial ratification: 29/08/2007

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Tipranavir (Aptivus®) should be recommended for use within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection, only for the treatment of highly pre-treated adult patients who have failed multiple protease inhibitors (PI), and where resistance profiling suggests it is appropriate. Use should be in accordance with the British HIV Association (BHIVA) guidance. Tipranavir (Aptivus®) is not presently recommended for shared care.
Final Appraisal Recommendation (FAR)
Download